Stock Upgrades Today See Wall Street Boost Confidence

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  11 Nov 2025
 

•   AMZN  
   
  -0.06%
•   CCI  
   
  +0.17%
•   DELL  
   
  -1.18%
•   DKNG  
   
  +0.96%
•   GGR  
   
  -1.96%

$AMZN Amazon continues to flex its retail dominance even beyond e-commerce headlines. The latest buzz around affordable under $50 might seem consumer-focused, but it reflects Amazon unmatched product diversity and brand ecosystem reach. With consistent engagement across both essential goods and lifestyle categories, the company shows no signs of slowing down heading into the holiday season a subtle but steady bullish signal for long-term investors.

$CCI Crown Castle received a reaffirmed Buy rating from KeyBanc following a strong third-quarter performance that underscored stability in its telecom infrastructure portfolio. The firm ongoing investments in 5G and small-cell deployments continue to support steady cash flow and dividend growth. For income-oriented traders, CCI consistent yield and improving fundamentals remain a solid defensive play in a volatile market.

$DELL Deutsche Bank upgrade on Dell Technologies reflects growing confidence in its rebound potential. After a strong Q3, analysts are urging investors to “buy the dip,” emphasizing that Dell exposure to enterprise demand, AI-driven infrastructure, and hybrid computing make it a compelling cyclical recovery story. While near-term volatility may persist, this call suggests room for upside as the company continues to integrate AI-focused server sales into its growth engine.

$DKNG Wall Street shuffled its ratings this week, with DraftKings emerging on the favorable side of the equation. Despite broader market caution, analysts see the digital gaming and sports betting leader as well-positioned ahead of major sporting events. DraftKings’ consistent revenue growth and expanding market presence continue to support the bullish outlook, even as competition heats up across states.

$GGR Gogoro latest quarterly report delivered a powerful reminder of the operational discipline. The EV battery-swapping pioneer posted rising gross margins, robust subscription growth, and sharply reduced inventory levels. Its expansion of the EZZY product line and progress toward higher-density battery packs position Gogoro as a leader in sustainable urban mobility. While the broader two-wheeler market faces headwinds, Gogoro efficient supply chain and strong cash generation suggest a durable foundation for long-term growth.

$LEVI Levi Strauss & Co. remains a timeless name in retail, and Stifel reaffirmed Buy rating with a $27 price target shows confidence in its steady brand execution. The denim icon strategic cost management, digital growth, and ongoing efforts to refresh product lines are resonating with consumers. Levis is proving that classic American brands can still find modern momentum when guided by smart, agile management.

$LLY Eli Lilly has been on an impressive run, with shares up 18% over the past month. The rally, fueled by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound, reflects a rare combination of commercial success and innovation depth. With upgraded guidance and strong market sentiment, analysts see further upside as Lilly solidifies its leadership in the weight-loss treatment space a sector rapidly reshaping healthcare valuations.

$MPWR William Blair reaffirmed Buy on Monolithic Power Systems highlights continued faith in the semiconductor stalwart profit resilience. MPWR third-quarter performance confirmed strong demand across automotive, data center, and industrial markets. The high-margin model and efficient execution give it a defensive edge even as chip stocks navigate cyclical swings.

$PCVX Vaxcyte continues to capture attention with TD Cowen reiterating its Buy rating and a $50 price target. The positive Phase II data have bolstered confidence in its next-gen vaccine platform. With hedge funds showing interest and 2026 catalysts ahead, Vaxcyte could emerge as one of biotech brightest early-stage growth stories if clinical momentum holds.

$QRVO Qorvo saw Mizuho lift its rating from Underperform to Neutral, with a raised price target reflecting improving fundamentals. The semiconductor maker exposure to RF chips and handset components has faced cyclical challenges, but cost discipline and inventory normalization appear to be paying off. Traders might view this as a turning point after months of cautious sentiment.

$RARE Ultragenyx gained fresh validation as Morgan Stanley reaffirmed its Buy rating and $55 target, citing a strong balance sheet and advancing rare-disease pipeline. While biotech sentiment can be fickle, Ultragenyx late-stage assets and disciplined execution continue to attract institutional interest looking for asymmetric risk-reward setups.

$VKTX Viking Therapeutics remains one of biotech hottest tickers after new VK2735 data showed promising obesity treatment results. William Blair reiterated Buy rating underscores confidence that Viking could follow in Lilly footsteps with differentiated therapies. Positive trial data and investor enthusiasm position VKTX as one of the most closely watched names in metabolic drug development.

$VOYA Voya Financial continues to impress analysts, with Morgan Stanley maintaining a Buy rating and a $91 price target after its Q3 earnings beat. The financial services firm is navigating a challenging rate environment with prudent capital management and strong operating leverage.

$WM Waste Management was upgraded to Outperform by Baird, reflecting optimism in the pricing power and sustainability initiatives. As infrastructure and recycling trends gain traction, WM stable cash flow profile and operational excellence make it a safe haven for conservative investors seeking growth with stability.

View All Headlines